| scholarly article | Q13442814 |
| P2093 | author name string | Bruce A Sullenger | |
| Seong-Wook Lee | |||
| Kyung-Sook Shin | |||
| P2860 | cites work | A genetic model for colorectal tumorigenesis | Q27860582 |
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| Surfing the p53 network | Q28032484 | ||
| p53 mutations in human cancers | Q28302973 | ||
| p53 mutant mice that display early ageing-associated phenotypes | Q29622826 | ||
| The effects of the adenovirus-mediated wild-type p53 delivery in human epithelial ovarian cancer cell line in vitro and in vivo | Q30307979 | ||
| One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity | Q30461490 | ||
| Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing | Q30465698 | ||
| Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. | Q30924713 | ||
| Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes | Q34365376 | ||
| P53 gene replacement for cancer--interactions with DNA damaging agents | Q34476655 | ||
| The promise and obstacle of p53 as a cancer therapeutic agent | Q34729245 | ||
| Targeted genetic repair: an emerging approach to genetic therapy | Q35190980 | ||
| Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts | Q37230210 | ||
| In vitro analysis of the dominant negative effect of p53 mutants | Q38334521 | ||
| Functional repair of a mutant chloride channel using a trans-splicing ribozyme | Q39740174 | ||
| Ribozyme-mediated trans-splicing of a trinucleotide repeat. | Q41051948 | ||
| Adenovirus-based p53 gene therapy in ovarian cancer. | Q41277773 | ||
| Genetic mechanisms of tumor suppression by the human p53 gene | Q41710706 | ||
| Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells | Q42812813 | ||
| Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing | Q43049074 | ||
| Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors | Q45887644 | ||
| Trans -splicing ribozymes for targeted gene delivery 1 1Edited by J. Karn | Q57902856 | ||
| A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice | Q72293593 | ||
| Molecular biology of breast cancer | Q72688334 | ||
| Evaluating and enhancing ribozyme reaction efficiency in mammalian cells | Q73719135 | ||
| P433 | issue | 2 | |
| P921 | main subject | ribozyme | Q205858 |
| P304 | page(s) | 365-372 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. | |
| P478 | volume | 10 |
| Q35985483 | Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer |
| Q52034065 | Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. |
| Q92864734 | At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids |
| Q90593392 | Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective |
| Q21245909 | Cactus pear: a natural product in cancer chemoprevention |
| Q45862174 | Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme |
| Q40307946 | Construction of retroviral vector of p(125FAK) specific ribozyme genes and its effects on BGC-823 cells |
| Q36240196 | Gene therapy progress and prospects: reprograming gene expression by trans-splicing |
| Q38205584 | Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. |
| Q41888497 | In vivo evolution of a catalytic RNA couples trans-splicing to translation |
| Q41861514 | In vivo excision of a single targeted nucleotide from an mRNA by a trans excision-splicing ribozyme |
| Q40093470 | In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells |
| Q39591944 | Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme |
| Q46423378 | Lariat capping as a tool to manipulate the 5' end of individual yeast mRNA species in vivo |
| Q36866549 | Modulating the expression of disease genes with RNA-based therapy. |
| Q42036073 | Nuclear group I introns in self-splicing and beyond |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q45867347 | Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement |
| Q38718304 | Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement |
| Q45885374 | Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript |
| Q28264210 | Spliceosome-mediated trans-splicing: the therapeutic cut and paste |
| Q35205340 | Spliceozymes: ribozymes that remove introns from pre-mRNAs in trans |
| Q35865503 | Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA Regulation |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q38891212 | Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells |
| Q35138721 | Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo |
| Q39945361 | Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo |
Search more.